Arixtra 2.5 mg/0.5 ml Injection
PDF Leaflet Revision Date: 19 April 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of venous thromboembolic events and acute coronary syndromes.
Dosage (summary)
2.5 mg once daily by subcutaneous injection; initial dose 6 hours post-surgery.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Body weight < 50 kg
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- NSAIDs
- Platelet inhibitors
- Fibrinolytics
Contraindications
- Hypersensitivity to fondaparinux
- Active major bleeding
- Severe renal impairment
- Infective endocarditis
- Body weight < 50 kg
Common side effects
- Bleeding
- Thrombocytopenia
- Nausea
- Headache
Counselling Points
- Administer subcutaneously, not intramuscularly.
- Monitor for signs of bleeding.
- Strict adherence to dosing schedule is crucial.
Serious warnings
- Risk of spinal/epidural hematomas
- Increased risk of bleeding in renal impairment
Important Disclaimer
The Arixtra 2.5 mg/0.5 ml Injection professional information leaflet below is the property of Pharmacare Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
